Neurochemical biomarkers in Alzheimer’s disease and related disorders
Neurochemical biomarkers for diagnosing dementias are currently under intensive investigation and the field is rapidly expanding. The main protagonists and the best defined among them are cerebrospinal fluid levels of Aβ42, tau and its phosphorylated forms (p-tau). In addition, novel cerebrospinal f...
Main Authors: | Mirko Bibl, Hermann Esselmann, Jens Wiltfang |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2012-11-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/1756285612455367 |
Similar Items
-
Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40ox% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
by: Mirko Bibl, et al.
Published: (2010-01-01) -
Should CSF Biomarkers Support a Routine Analysis for Early Diagnosis of Alzheimer's Disease?
by: Lucilla Parnetti, et al.
Published: (2010-01-01) -
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
by: Nicholas J. Ashton, et al.
Published: (2019-12-01) -
The thalamus in Alzheimer's and Parkinson's disease : a neuropathological and neurochemical study
by: Xuereb, John H.
Published: (1989) -
Higher Level of Mismatch in 4 Carriers for Amyloid-Beta Peptide Alzheimer’s Disease Biomarkers in Cerebrospinal Fluid
by: Jonathan Vogelgsang, et al.
Published: (2019-05-01)